Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
202 results about "IOP - Intraocular pressure" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Glaucoma treatment kit
A glaucoma treatment kit, containing intraocular stents and applicators, is disclosed. The stents are configured to extend between the anterior chamber and Schlemm's canal of the eye, for enhancing outflow of aqueous from the anterior chamber so as to reduce intraocular pressure.
Owner:GLAUKOS CORP
Injectable glaucoma implants with multiple openings
InactiveUS20050266047A1Faster and safe and less-expensive surgical procedureRapid visual recoveryOrganic active ingredientsEye surgerySchlemm's canalImplant
Intraocular stents and applicators are disclosed for treating glaucoma. The stents are configured to extend between the anterior chamber of the eye and Schlemm's canal for enhancing outflow of aqueous from the anterior chamber so as to reduce intraocular pressure. The stents can have features for anchoring the stent into Schlemm's canal as well as preventing the walls of Schlemm's canal from closing the outlet of the stents. The applicators can be steerable so as to make implantation easier. Additionally, the applicators can be configured to hold a plurality of stents so that multiple stents can be implanted through one incision without removing the applicator from the incision between serial implantations.
Owner:GLAUKOS CORP
Sensor contact lens, system for the non-invasive monitoring of intraocular pressure and method for measuring same
The invention is characterized in that it comprises a truncated contact lens (1), whose truncation plane is parallel to the base of said contact lens, and a polymeric nanocomposite material (2) centrally disposed and attached to the perimeter of the truncated area, said material being sensitive to pressure changes, biocompatible and transparent, and including contact electrodes (3), and in that it also comprises means for transmitting IOP measurement data to an external system. The invention also relates to a method for measuring IOP using said lens comprising: i) placing said sensor contact lens in the eye to determine its intraocular pressure; ii) providing a direct current value between external electrodes; iii) ΔV measurement between internal electrodes; and iv) identifying whether the value obtained is outside the linear response, expressed in changes of resistivity, of the polymeric nanocomposite material. The invention also relates to a telemetry system comprising said lens.
Owner:CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) +4
Treatment of eye disorders using articulated-arm coupled ultraviolet lasers
InactiveUS20060129141A1Increase flexibilityIncrease spacingLaser surgerySurgical instrument detailsIntra ocular pressureDisease
Surgical method and apparatus for presbyopia correction and glaucoma by laser removal a portion of the sclera and / or ciliary tissue are disclosed. The disclosed preferred embodiments of the system consists of a beam spot controller, an articulated arm and an attached end-piece. The basic laser beam includes UV laser having wavelength ranges of (0.19-0.36) microns, generated from UV excimer lasers of ArF, XeCl or solid state lasers of Nd:YLF, Nd:YAG, Ti:sapphire with harmonic generation using nonlinear crystals. Presbyopia is treated by ablation of the treated surface tissue in predetermined patterns outside the limbus to increase the accommodation of the eye. Glaucoma is treated by decreasing of intra ocular pressure of the laser surgery.
Owner:NEW VISION
Methods and devices for draining fluids and lowering intraocular pressure
ActiveUS7354416B2Prevent and deter cloggingPrevent unwanted backflow of fluidEye implantsEye surgerySubarachnoid spaceOptic nerve
Methods, devices and systems for draining fluid from the eye and / or for reducing intraocular pressure. A passageway (e.g., an opening, puncture or incision) is formed in the lamina cribosa or elsewhere to facilitate flow of fluid from the posterior chamber of the eye to either a) a subdural location within the optic nerve or b) a location within the subarachnoid space adjacent to the optic nerve. Fluid from the posterior chamber then drains into the optic nerve or directly into the subarachnoid space, where it becomes mixed with cerebrospinal fluid. In some cases, a tubular member (e.g., a shunt or stent) may be implanted in the passageway. A particular shunt device and shunt-introducer system is provided for such purpose. A vitrectomy or vitreous liquefaction procedure may be performed to remove some or all of the vitreous body, thereby facilitating creation of the passageway and / or placement of the tubular member as well as establishing a route for subsequent drainage of aqueous humor from the anterior chamber, though the posterior chamber and outwardly though the passageway where it becomes mixed with cerebrospinal fluid.
Owner:QUIROZ MERCADO HUGO +1
RNAi-mediated inhibition of ocular hypertension targets
InactiveUS20060172963A1Lower eye pressureOrganic active ingredientsSenses disorderIntra ocular pressureATPase
RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+ / K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.
Owner:ARROWHEAD RES CORP +1
Implants for reducing intraocular pressure
InactiveUS20120203160A1Easy to moveLower eye pressureEye surgeryPharmaceutical delivery mechanismSchlemm's canalWave shape
The present invention provides ocular implants adapted to reside in Schlemm's canal for reducing intraocular pressure of an eye and methods for using the same. In some embodiments the ocular implants comprise a thin rod adapted and configured to extend in a curved volume in Schlemm's canal. The thin rod comprises a plurality of wave-shaped segments such that a sufficient number and amount of wave-shaped segments extend to the inner wall of the trabecular meshwork and to the outer wall of Schlemm's canal thereby keeping Schlemm's canal open.
Owner:UNIV OF COLORADO THE REGENTS OF
Use Of A Viscoelastic Composition For Treating Increased Intraocular Pressure
ActiveUS20080058760A1Increased intraocular pressureRapid and cost-effectiveSenses disorderPharmaceutical delivery mechanismFistulaMedical device
A viscoelastic medium is useful for the manufacture of a medicament, such as a medical device, for treatment of increased intraocular pressure in the eye of a human or animal. The medicament is administerable into at least one sclerally penetrating fistula of the eye such that the fistula is filled with the medicament. The medium is also useful in a method of treating increased intraocular pressure in the eye of a human or an animal in need thereof, comprising the step of injecting the viscoelastic medium into at least one sclerally penetrating fistula in the eye such that the fistula is filled with the medium.
Owner:Q MED AB
Cytoskeletal active agents for glaucoma therapy
InactiveUS20020045585A1Lower eye pressureImprove fluid flowBiocideSenses disorderActin cytoskeletonActive agent
Methods for the treatment of glaucoma are provided by the present invention. The compounds described cause a perturbation of the actin cytoskeleton in the trabecular meshwork or the modulation of its interactions with the underlying membrane. Perturbation of the cytoskeleton and the associated adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
Owner:YEDA RES & DEV CO LTD +1
Pyranoindazoles and their use for the treatment of glaucoma
InactiveUS6696476B2Good chemical stabilityOrganic active ingredientsBiocideElevated intraocular pressureTreatment glaucoma
Owner:NOVARTIS AG
Methods for treating eye conditions
InactiveUS8827990B2Lower eye pressureReduce pressureLaser surgeryDiagnosticsConjunctivaSinus venosus sclerae
Owner:BIOLASE INC
Intraocular physiological sensor
An intraocular pressure (IOP) sensing system may comprise an intraocular pressure sensing implant to be implanted into the eye of a patient for capturing absolute intraocular pressure measurements and an external device for capturing atmospheric pressure measurements. The intraocular pressure sensing implant may be configured to capture an absolute intraocular pressure measurement at an appointed time, and the external device may be configured to capture a plurality of atmospheric pressure measurements around the appointed time.
Owner:GLAUKOS CORP
Self Sealing Cannula / Aperture Closure Cannula
A cannula having a body, a sealing disc, and a cap. The sealing disc is located within the body and is compressed by the cap. An angled cut in the sealing disc allows microsurgical instruments to be inserted through the cannula into the eye. Upon removal, the cut in the sealing disc closes, preventing the loss of intraocular pressure.
Owner:ALCON INC
Portable non-contact tonometer and method of determining intra-ocular pressure using such
ActiveUS20100030056A1Simple procedureEasy to measureTonometersOperating instructionNon contact tonometer
A portable non-contact tonometer (2) for measuring Intra-Ocular Pressure (IOP) of subject's eye is presented. In its preferred embodiment tonometer (2) is designed to be operated by the subject himself. It is housed in a hand-held case (4) which contains compressed air source (40), eye alignment detectors (12, 14), cornea applanation detector system (8, 10), a pressure sensor (32) and optical system for presenting gaze target (48).The animated gaze target (48) advantageously draws subject's attention to itself and keeps his eye (62) in alignment long enough for the measurement to take place, while optionally displaying system status and operating instructions. An audio annunciation system (16) guides the subject in the operation of the tonometer and prepares him for the actual procedure. The timing of the air puff is randomized to prevent subject's conditioning. The overall operation of the tonometer is controlled by a built-in microprocessor (50) system.In one of the tonometer embodiments (2B) a 3-D map of cornea is computed and a technique to compute the IOP derived from the difference of 3-D corneal maps before and during the air puff application is disclosed.
Owner:ABRAMOV IGOR
Illumination system and method
The invention relates to an illumination system (10) and an illumination method for an opthalmological analysis apparatus, in particular an analysis apparatus for measuring an intraocular pressure in an eye, wherein the analysis apparatus includes an actuation device (11) with which a puff of air for deforming a cornea (14) can be applied to the eye (12) in the direction of an optical axis (15) of the eye, wherein the illumination system includes at least one illumination device (23) with which the cornea of the eye can be illuminated by a slit light in such a way that a sectional image (27) can be generated in an illumination plane coinciding with the optical axis, wherein the illumination device is formed so that an illuminating beam path (28) of the illumination device oriented towards the eye is arranged at an angle α relative to the optical axis (15).
Owner:OCULUS OPTIKGERATE GMBH
Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
InactiveUS20030181503A1Good chemical stabilityBiocideSenses disorderOphthalmologyElevated intraocular pressure
Owner:NOVARTIS AG
Device for treating ocular diseases caused by increased intraocular pressure
InactiveUS20160302967A1Increased intraocular pressureDecreasing tube exposure dangerEye surgeryWound drainsDonated tissueBaerveldt Implants
One or more example embodiments relate to a device for treating ocular diseases caused by an increased intraocular pressure. The device for treating ocular diseases according to one or more example embodiments, compared to a conventional Ahmed valve implant and Baerveldt implant, does not require a donated tissue, reduces tube exposure danger, allows intraocular pressure to be easily controlled after surgery, has a slight effusion of aqueous humor to the surrounding due to a small perforated window, decreases the types and number of postoperative interventions, and decreases the number of patients with early postoperative complications.
Owner:SAMSUNG LIFE PUBLIC WELFARE FOUND
Cytoskeletal active compounds, compositions and use
InactiveUS20060217427A1Increase intraocular pressureAlter the actin cytoskeletonBiocideSenses disorderOpen angle glaucomaDrug
The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.
Owner:INSPIRE PHARMA
Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
InactiveUS20030083346A1Good chemical stabilityReduce controlBiocideSenses disorderElevated intraocular pressureAzole
Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of the present invention.
Owner:ALCON INC
Closed Microfluidic Network for Strain Sensing Embedded in a Contact Lens to Monitor IntraOcular Pressure
ActiveUS20190076021A1Easy to manageEasy usabilityStrain gaugeTonometersMechanical stretchingIntraocular pressure
A microfluidic strain sensing device for monitoring intraocular pressure. The device has a contact lens and a closed microfluidic network embedded with the contact lens. The network has a volume that is sensitive to an applied strain. The network distinguishes: (i) a gas reservoir containing a gas, (ii) a liquid reservoir containing a liquid that changes volume when the strain is applied, and (iii) a sensing channel able to hold the liquid within the sensing channel. The sensing channel connects the gas reservoir on one end and connects the liquid reservoir on another end. The sensing channel establishes a liquid-gas equilibrium pressure to interface and equilibrium within the sensing channel, which would fluidically change as a response to radius of curvature variations on a cornea, or as a response to mechanical stretching and release of the cornea. The liquid-gas equilibrium pressure interface and equilibrium are used for measuring the intraocular pressure.
Owner:SMARTLENS INC
Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates
InactiveUS7030250B2Simple methodOptically-active compound separationBulk chemical productionThiopyranElevated intraocular pressure
The process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides (I) wherein R1 is H or C1-5 alkyl, and R2 is C1-5 alkyl, starts from the corresponding 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-7,7-dioxides, and comprises protecting the alkylamine group, introducing a sulfonamide group and eliminating protecting group. Some compounds of formula (I) are inhibitors of the carbonic anhydrase and can be used in the treatment of elevated intraocular pressure
Owner:RAGACTIVES SL
Uridine di- or tri-phosphate derivatives and uses thereof
The invention provides particular uridine di- and tri-phosphate derivatives, and pharmaceutical compositions thereof. These compounds are useful for treatment of diseases, disorders and conditions modulated by P2Y6 receptors, and particularly for lowering intraocular pressure and thereby treating ocular hypertension and / or glaucoma.
Owner:BAR ILAN UNIV +1
Eye tonometry apparatus, systems and methods
A system for measuring intraocular pressure (IOP) of an eye, comprising a plurality of force sensors that are adapted to contact a surface of an eye, means for measuring the forces exerted on the force sensors when in contact with the eye surface, and processing means that is adapted to receive the measured forces and determine IOP of the eye as a function of the measured forces.
Owner:ENIKOV ENIKO TODOROV +1
Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
InactiveUS7094761B2Modulate activitySenses disorderPeptide/protein ingredientsElevated intraocular pressureInhibitor/antagonist
A GPCR-like protein is described, as well as inhibitory / antagonistic compounds and compositions comprising such inhibitors / antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.
Owner:THERATECHONOLGIES INC
Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
InactiveUS20060292613A1Senses disorderPeptide/protein ingredientsOphthalmologyElevated intraocular pressure
Owner:THERATECHONOLGIES INC
Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
Disclosed are (N)-methanocarba adenine nucleosides, e.g., of the formula (I): as A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein A, a, R2, and R3 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. Also disclosed are conjugates comprising a dendrimer and one or more ligands, which are functionalized congeners of an agonist or antagonist of a receptor of the G-protein coupled receptor (GPCR) superfamily. Such conjugates are have the potential of being used as dual agonists, dual antagonists, or agonist / antagonist combinations.
Owner:UNITED STATES OF AMERICA
Apparatus and methods for treating excess intraocular fluid
ActiveUS10603214B2Minimize buildupAvoiding hypotonyEye surgeryFlexible member pumpsElevated intraocular pressureControl cell
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)
Ep2 agonists
InactiveUS20080045545A1Improve propertiesOvercome inherent deficiencyBiocideSenses disorderAgonistTreatment glaucoma
The invention provides EP2 agonists, methods for their preparation, pharmaceutical compositions containing these compounds, and methods of using these compounds and compositions for lowering intraocular pressure and thereby treating glaucoma.
Owner:PFIZER INC
Method and system for laser automated trabecular excision
Owner:GOOI PATRICK +1
Method of reducing intraocular pressure in humans
Provided herein are compounds of Formula I, compositions comprising an effective amount of a compound of Formula I, and methods for reducing intraocular pressure comprising administering an effective amount of compounds of Formula I to a subject in need thereof.
Owner:INOTECK PHARMA CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com